NGNE
Neurogene Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.58
+3.41%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$27.72
From 52W high−35.62%
Volume208553.00
Market cap$551.91M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$27.72
From 52W high
−35.62%
Volume
208553.00
Market cap
$551.91M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.1x
P/E (TTM)
—
RSI (14)
48.0
MomentumView details →
1D Return
+3.41%
YTD Return
+28.57%
SummaryUpdated Jun 1, 2026
Neurogene Inc. (NASDAQ:NGNE) is a clinical-stage biotechnology company founded in 2014 and headquartered in New York, New York. The company specializes in developing gene therapies for rare neurological diseases, focusing on conditions that primarily affect children and have limited or no treatment options. Since its initial public offering in 2014, Neurogene has been advancing its pipeline of investigational treatments through clinical trials, with its lead programs targeting Rett syndrome and Batten disease.
Similar companies
Latest newsMore news →
Neurogene announced that it will present data from its NGN-401 gene therapy program at the Neurogene Inc. in Hamburg on October 27–30, 2026.16d agoNeurogene Inc. granted non-qualified stock options to purchase an aggregate of 8,340 shares of its common stock to five new employees on October 5, 2026.30d agoNeurogene Inc. granted non-qualified stock options to purchase 38,330 shares of common stock to two new employees as inducement grants on September 1, 2026.61d ago